Prospective multicenter evaluation of glycemic and patient-reported outcomes following transition to a next-generation continuous glucose monitoring system in users of advanced hybrid closed-loop technology

Therapeutic Advances in Endocrinology and Metabolism 2026 Open access

Read full text
Authors: Lía Nattero-Chávez, MAR LORENZO, María Soledad Ruiz de Adana, Olga Simó-Servat, Mercè Abad, Carmen Quirós, María Durán Martínez, Alejandra Quintero Tobar, Ane Bayona, Teresa Ruiz Gracia, Esther de la Calle de la Villa, María José Picón
DOI: 10.1177/20420188251407515
Cited by: 4
References: 24

Abstract

Aims: To assess the real-world impact of transitioning from the Dexcom G6 ® to G7 ® system in individuals with type 1 diabetes (T1D) using the Tandem t:slim X2™ with Control-IQ™. Primary outcomes included glycemic control changes, while secondary outcomes evaluated patient-reported outcomes (PROMs) and experiences (PREMs). Methods: A 3-month prospective, multicenter, observational study was conducted in individuals previously using Dexcom G6 and Control-IQ. Glycemic control was assessed via TIR 70–180 and HbA 1c . PREMs and PROMs were measured using validated questionnaires (Diabetes Quality of Life (DQoL), Type 1 Diabetes Life (ViDa1), Diabetes Distress Scale (DDS), and Diabetes Treatment Satisfaction Questionnaire). Statistical analyses were stratified by baseline TIR 70–180 (>70% vs

Fields of Study & Subjects

Diabetes Management and Research Diabetes Management and Education Mobile Health and mHealth Applications

Publication details

Journal / source
Therapeutic Advances in Endocrinology and Metabolism
Publisher
SAGE Publications
Volume
17
Pages
20420188251407515–20420188251407515
Publication date
17 January 2026
Language
EN